Cuprina MENA Co. Ltd, a 49%-owned associate of Cuprina Holdings (Cayman) Ltd, has completed the establishment of a laboratory in Saudi Arabia designed to manufacture MEDIFLY maggot debridement therapy for chronic wound treatment. This new facility will supply the therapy throughout the Middle East and North Africa region. Additionally, Cuprina MENA has acquired exclusive rights to market medicinal leeches in the Gulf Cooperation Council countries, a treatment increasingly used for medical conditions such as venous congestion and to enhance tissue healing post-surgery. These strategic advancements are expected to broaden Cuprina's market presence in the MENA and GCC regions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.